Access the full text.
Sign up today, get DeepDyve free for 14 days.
P. Silver, Linda Hamel, R. Bentley, K. Dillon, M. Connell, B. O'Connor, R. Ferrari, E. Pagani (1990)
Inhibition of cardiovascular low‐Km cAMP phosphodiesterase activity by medorinoneDrug Development Research, 21
(1990)
Biochemical and pre-clinical pharmacology of selective inhibitors of cardiovascular phosphodiesterase isozymes
C. Lambert, W. Nichols, C. Pepine (1983)
Indices of ventricular contractile state: comparative sensitivity and specificity.American heart journal, 106 1 Pt 1
N. Komas, C. Lugnier, A. Bec, C. Gal, G. Barthelemy, J. Stoclet (1989)
Differential Sensitivity to Cardiotonic Drugs of Cyclic AMP Phosphodiesterases Isolated from Canine Ventricular and Sinoatrial‐Enriched TissuesJournal of Cardiovascular Pharmacology, 14
R. Lee, Dale Evans, S. Baky, R. Laffan (1975)
Pharmacology of nadolol (SQ 11725), a beta-adrenergic antagonist lacking direct myocardial depression.European journal of pharmacology, 33 2
(1988)
The inotropic and vasodilatory activity of medorinone in dogs
(1988)
In vitro cardiovascular phosphodiesterase inhibition and in vivo cardiovascular activity of milrinone in dogs
D. Baim, D. Baim, A. McDowell, A. McDowell, J. Cherniles, J. Cherniles, E. Monrad, E. Monrad, J. Parker, J. Parker, J. Edelson, J. Edelson, E. Braunwald, E. Braunwald, W. Grossman, W. Grossman (1983)
Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure.The New England journal of medicine, 309 13
B. Brenner, K. Duchin, I. Ichikawa, J. Pfeffer, M. Pfeffer (1984)
Comparative effects of propranolol and nadolol on renal blood flow in normal rats and rats with congestive heart failure.American heart journal, 108 4 Pt 2
The mixed two - factor design
A. Defelice, A. Brousseau (1988)
Natriuretic and vasodilating activities of intrarenally administered atriopeptin II, substance P and bradykinin in the dog.The Journal of pharmacology and experimental therapeutics, 246 1
K. Weber, J. Janicki, C. Campbell, R. Replogle (1987)
Pathophysiology of acute and chronic cardiac failure.The American journal of cardiology, 60 5
G. Naccarelli, R. Goldstein (1989)
Electrophysiology of phosphodiesterase inhibitors.The American journal of cardiology, 63 2
(1982)
P-Blockers and renal function
P. Silver, R. Lepore, P. Canniff, B. O'Connor, Bernhard Lemp, A. Harris (1990)
Activation of the cAMP system by medorinone correlates with positive inotropy or vasorelaxationDrug Development Research, 21
(1990)
Does cyclic AMP provoke ventricular fibrillation ?
M. Kawada, K. Satoh, N. Taira (1986)
Cardiohemodynamic effects of nipradilol (K-351) in the dog: comparison with propranolol, nadolol and prazosin.Japanese journal of pharmacology, 42 1
J. Bradford, H. Dean (1894)
The Pulmonary Circulation 1The Journal of Physiology, 16
The hemodynamic effects of the low Km cAMP peak III PDE inhibitor medorinone (0.01–0.3 mg/kg, i. v. ) were evaluated in anesthetized dogs in the presence and absence of β‐adrenoreceptor blocked. Medorinone increased the peak derivative of left ventricular pressure (+ dP/dt) in non‐blocked (all doses) and β‐blocked dogs (≥0.03 mg/kg) (2,766±259 and 1,403±262 mm Hg/sec, respectice max. changes). Heart rate (HR) was increased by medorinone in non‐blocked (≥0.1 mg/kg) and β‐blocked dogs (≥0.03 mg/kg) (77.4±8.9 and 25.5±4.3 beats/min, respective max. changes). In non‐blocked dogs only, medorinone (all doses) decreased left ventricular end‐diastolic pressure (LVEDP) (7.7±1.7 mm Hg, max. change). Mean arterial pressure (MAP) was similarly decreased by medorinone (<0.03 mg/kg) in β‐blocked and non‐blocked dogs (max. approx. −27 mm Hg). Medorinone did not affect cardiac output or renal blood flow. The hemodynamics of medorinone and milrinone (another peak III PDE inhibitor) in non‐blocked dogs were similar, except meddorinone was less potent in increasing +dP/dt (2,766±259 vs. 3,747±388, max. changes) and more potent in reducing LVEDP (−7.7±1.7 vs. −1.8±1.2 mm Hg, max. changes). In conclusion, medorinone similarly reduced MAP, but more effectively decreased preload, increased inotropy and chronotropy in non‐blocked than β‐blocked anesthetized dogs. Medorinone is more potent in reducing preload, but less potent in enhancing inotropy when compared to milrinone in anesthetized dogs.
Drug Development Research – Wiley
Published: Jan 1, 1990
Keywords: medorinone; cardiovascular hemodynamics; phosphodiesterase inhibitors
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.